Month: January 2026

Introduction: Erectile Dysfunction as a Metabolic Signal, Not a Local Problem Erectile dysfunction (ED) is often misinterpreted as an isolated disorder of sexual performance. In reality, it represents one of the most sensitive clinical indicators of systemic vascular health. The…

Introduction: When Vascular Medicine Meets Real Life The coexistence of erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and arterial hypertension is not a coincidence—it is a predictable consequence of vascular aging. As men grow older, endothelial dysfunction quietly reshapes both…

Introduction: When Similar Molecules Behave Very Differently Pulmonary arterial hypertension (PAH) is a disease defined by precision. Small changes in pulmonary vascular resistance, right ventricular afterload, or oxygenation can translate into large differences in symptoms, functional capacity, and survival. As…

Introduction: When One Mechanism Is No Longer Enough Benign prostatic hyperplasia (BPH) is no longer viewed as a purely anatomical problem of prostate enlargement. It is a chronic, progressive condition characterized by a complex interaction of hormonal, vascular, neuromuscular, and…

Introduction: Lower Urinary Tract Symptoms as a Systemic Problem Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) represent one of the most common chronic conditions affecting aging men. Their prevalence increases steadily with age, and by middle…

Introduction: Solubility as the Quiet Gatekeeper of Oral Therapy In oral drug development, few parameters wield as much influence—and cause as much frustration—as intestinal solubility. A compound may exhibit excellent potency, target selectivity, and metabolic stability, yet fail clinically because…

Introduction: Why Timing May Matter More Than We Thought Erectile dysfunction following radical prostatectomy remains one of the most clinically frustrating and emotionally charged consequences of otherwise successful prostate cancer surgery. Even in the era of nerve-sparing robot-assisted radical prostatectomy…

Introduction: When the Best Therapy Works Only If It Is Taken Pulmonary arterial hypertension (PAH) is a disease that does not forgive inconsistency. Its pathophysiology is relentless, progressive, and largely indifferent to intention. Over the past two decades, the therapeutic…

Introduction: Nitric Oxide Beyond Mammals Nitric oxide (NO) occupies a privileged position in cardiovascular physiology. In mammals, it is almost impossible to discuss vascular tone, endothelial function, or smooth muscle relaxation without invoking the NO–cGMP signaling cascade. Over decades, this…

Introduction: When Manufacturing Parameters Become Therapeutic Variables In modern pharmaceutical technology, the distance between formulation science and clinical outcome is far shorter than it once appeared. A decision made at the level of processing pressure or mechanical conditioning may ultimately…

Radical prostatectomy remains a cornerstone in the management of localized prostate cancer. Advances in surgical technique—particularly nerve-sparing approaches—have transformed oncological outcomes while preserving quality of life. Yet even with meticulous nerve preservation, erectile dysfunction (ED) continues to be one of…

Modern urology increasingly favors minimally invasive solutions. Prostatic artery embolization (PAE) has emerged as an attractive alternative to traditional surgical interventions for benign prostatic hyperplasia (BPH), offering symptom relief without tissue resection and with a lower risk of sexual dysfunction….

Pulmonary arterial hypertension (PAH) has long been described in textbooks as a rare disease of younger patients, often women, with few comorbidities and a clean cardiovascular background. That image is now largely obsolete. Contemporary registries and everyday clinical practice tell…

Erectile dysfunction (ED) is often treated as a local mechanical problem with a systemic medication. That sentence sounds contradictory, but it’s an accurate summary of modern practice. We prescribe phosphodiesterase type 5 inhibitors (PDE5 inhibitors) to improve penile blood flow,…

Lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) are two conditions that like to arrive as a pair—especially as men age. Many patients come in talking about urinary frequency, nocturia, weak stream, or…

Phosphodiesterase type 5 (PDE5) inhibitors—sildenafil, tadalafil, vardenafil, and avanafil—changed erectile dysfunction (ED) care more than any marketing campaign could ever claim. They offered a reliable oral option, moved ED treatment out of the “awkward procedures” category, and gave patients back…

Neurodegeneration is often introduced with a gloomy statistic—and for once, the gloom is justified. Dementia affects tens of millions of people worldwide and is expected to rise dramatically as populations age. In parallel, the therapeutic toolbox for Alzheimer’s disease (AD)…

Erectile function (EF) recovery after bilateral nerve-sparing radical prostatectomy (nsRP) is one of the most emotionally charged “numbers” in modern urology. Not because clinicians enjoy questionnaires, but because patients do. A man can accept a scar, tolerate transient fatigue, and…

Heart failure rarely begins with drama. It begins quietly—an ejection fraction that slips below normal, a ventricle that remodels, a left atrium that enlarges—while the patient still insists they feel “fine.” This stage, commonly called preclinical systolic dysfunction (PSD) and…

Erectile dysfunction (ED) drugs are often discussed in the language of convenience: “quick onset,” “long duration,” “works when you need it.” That framing is practical, but biologically incomplete. Phosphodiesterase type 5 (PDE5) inhibitors do not operate only in the penis;…

Radical prostatectomy remains one of the most effective curative options for localized prostate cancer. The surgery is technically elegant, oncologically meaningful, and—if you ask most patients—life-saving. Then the postoperative reality arrives with less elegance: erectile dysfunction (ED) and urinary incontinence…

Erectile dysfunction (ED) is often described in textbooks with neat definitions, but in real clinics it behaves like a chronic condition with mood swings. A patient may do “fine” for months, then relapse after stress, vascular progression, or simply aging…

Introduction: Oral Drug Absorption Begins with Dissolution, Not with Hope Oral administration remains the dominant route for drug delivery, not because it is perfect, but because patients tolerate it and regulators understand it. Yet, from a biopharmaceutical perspective, swallowing a…

Introduction: Erectile Dysfunction as a Multisystem Disorder, Not a Local Accident Erectile dysfunction (ED) is often introduced in textbooks as a mechanical failure of penile blood flow, but in real clinical practice it behaves more like a systemic barometer. It…

Introduction: Why Reperfusion Injury Remains the Achilles’ Heel of Lung Transplantation Despite remarkable advances in surgical technique, donor management, and perioperative care, lung transplantation continues to be burdened by a complication as old as the procedure itself: ischemia–reperfusion injury. Clinically,…

Introduction: Why Drug Interactions Matter More Than Ever in PAH Pulmonary arterial hypertension (PAH) has evolved dramatically over the past three decades. Once a rapidly fatal disease with limited therapeutic options, it is now a chronic condition managed through sophisticated,…

Introduction: Erectile Dysfunction as a Silent Burden of Chronic Renal Failure Chronic renal failure (CRF) is no longer viewed solely as a disorder of impaired filtration and metabolic imbalance. Modern clinical practice increasingly recognizes CRF as a systemic disease with…

Introduction: Erectile Dysfunction Beyond Sexual Performance Erectile dysfunction (ED) has long ceased to be viewed merely as a disorder of sexual performance. In modern clinical medicine, ED is increasingly recognized as a sentinel marker of systemic vascular pathology, often preceding…

Introduction: Drug-Induced PAH Is Rare—Until It Is Not Pulmonary arterial hypertension (PAH) is often taught as a disease of idiopathic mutations, connective tissue disorders, or congenital heart disease. In daily practice, however, clinicians increasingly encounter PAH as an iatrogenic condition,…

Introduction: Peyronie’s Disease Is Not “Just Curvature” Peyronie’s disease (PD) is sometimes described too politely—as if it were merely an anatomic deviation that can be measured with a protractor and fixed with a procedure. In reality, PD is a fibroproliferative…